Tag: Dupilumab

Affecting more than 28 million people in the U.S., asthma is a prevalent chronic disease, with 5-10% of cases being severe [1.6.1, 1.12.2]. For these individuals, the question 'Is Tezspire better than Dupixent?' is critical in finding effective treatment.

More than 850,000 patients globally are being treated with Dupixent for various inflammatory conditions. For those with nasal polyps, a key question is: **How long do you have to take DUPIXENT for nasal polyps?** This treatment is generally considered a long-term maintenance therapy.

While less common, swollen lymph nodes, or lymphadenopathy, are a reported side effect associated with the use of Dupixent (dupilumab). This reaction can stem from various causes, including hypersensitivity, and in rarer cases, is linked to more complex immune responses or even unmasking underlying conditions.

According to instructions for use, DUPIXENT (dupilumab) is administered as a subcutaneous injection, and the thigh is one of the recommended self-injection sites. Mastering the correct technique on how to give DUPIXENT injection in thigh ensures safe and effective delivery of the medication while minimizing discomfort.

According to official DUPIXENT prescribing information for patients with chronic obstructive pulmonary disease (COPD), diarrhea was reported in 3.7% of patients receiving a 300 mg dose in clinical trials. While this indicates that DUPIXENT can cause diarrhea, it remains a relatively infrequent side effect compared to others. This guide explores the details of this potential gastrointestinal issue, including its prevalence, possible causes, and effective management strategies.

According to a 2024 meta-analysis, both Dupixent and Xolair have generally favorable safety profiles, with neither being significantly associated with an increased risk of serious adverse events overall. However, determining which is safer, Xolair or Dupixent, depends heavily on a patient's individual health profile, as each medication has distinct side effect risks. A personalized risk-benefit assessment with a healthcare provider is essential for making an informed treatment decision.

Nemluvio (nemolizumab) is a newer biologic for atopic dermatitis (AD) and prurigo nodularis (PN), entering a market where Dupixent (dupilumab) has been an established treatment for years. To determine if **is Nemluvio better than Dupixent** for a specific patient, it's crucial to evaluate their different mechanisms, administration schedules, and side effect profiles with a healthcare provider.

In clinical trials, a percentage of patients treated with Dupixent (dupilumab) reported adverse reactions, including frequent eye problems and injection site reactions. For many, understanding what is the downside of Dupixent is a crucial step in evaluating if the therapeutic benefits outweigh the potential side effects, high cost, and specific warnings associated with this biologic medication.

Over one-third of adults and children with moderate-to-severe atopic dermatitis, or eczema, who used Dupixent (dupilumab) saw significant improvements in their symptoms in clinical trials. This medication offers a different approach to managing the chronic inflammatory condition by targeting the root cause from within the body, rather than just treating symptoms on the surface.

Injection site reactions are one of the most common side effects of Dupixent, with pain being a frequent complaint [1.2.4, 1.2.6]. But why is Dupixent so painful? Several factors, from medication temperature to injection technique, contribute to this discomfort.